RECAP ESMO 2026 — 117 trials, 1,732 results slides and physician reactions, all in one place See ESMO 2026 results →
Joshua Sabari, MD profile photo
KOL Pulse Profile · 2026

Joshua Sabari, MD

@JSabari · USA
Thoracic Medical Oncologist · NYU Langone Perlmutter Cancer Center · Institution profile ↗

Thoracic medical oncologist, Perlmutter Cancer Center NYU Langone Health. Tweets are my own and not medical advice

Joshua Sabari, MD (@JSabari) ranks #47 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 4 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $154,263 in 2025 general payments.

Joshua Sabari, MD, top 50 lung cancer KOL in the USA, KOL Pulse 2026 rankings
Joshua Sabari, MD, top 50 lung cancer KOL in the USA, KOL Pulse 2026 rankings

At a Glance

This Month

What Joshua Sabari, MD has posted in the last 30 days. Updated November 10, 2026.

No trial posts in the last 30 days.

2026 Rankings

ListUS rankGlobal rankPhysicians engagedPhysician engagements
Lung Cancer#47—45Full ranking

From the Podium, 2025–26

Talks, posters and sessions Joshua Sabari, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.

What Colleagues Are Saying About Joshua Sabari, MD

2026 posts by fellow physicians that mention @JSabari, quoted word for word.

Tox-Check: anti-EGFR drugs we use for mEGFR non-small cell #LungCancer w/ #AzamFarooqui & @JSabari ✅ Afatinib ✅ Osimertinib ✅ Amivantamab + Lazertinib Full 🗣️: ⭐️ OncBrothers & @OncUpdates Website ⭐️ Also on “Oncology Brothers” podcast #lcsm #OncTwitter #MedTwitter https://t.co/7Li6axST8G
Oncology Brothers (@OncBrothers) · · View on X ↗
How do we approach borderline resectable EGFR mutant NSCLC: NeoADAURA or LAURA? Debate at #DCLung26 with Drs. @JSabari and @JuliaRotow made great points. The room went with NeoADAURA but great case made for both shows how each case is unique. https://t.co/JMP7RhXTH3
Stephen V Liu, MD (@StephenVLiu) · · View on X ↗
Debating whether to use NEOADAURA vs LAURA @JSabari @JuliaRotow which one should we choose? @Joshua_Reuss @StephenVLiu @chulkimMD #DCLung26 https://t.co/jIVkSkxLvC
Dr. Nagla Abdel Karim (@NaglaAKarimMD) · · View on X ↗
How should we approach borderline resectable EGFR mutated NSCLC? Levity with a left hook on LAURA by @JSabari vs elegant retort on NEOADURA by @JuliaRotow @Sam_Rosner_ @Joshua_Reuss #DCLung26 https://t.co/zUtEO50YtZ
Hyein Jeon, MD (@HyeinJeon_MD) · · View on X ↗

Industry Payments

CMS Open Payments · 2025 general payments
$154,263 across 112 payments
View the CMS record ↗
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.

FAQ

How does Joshua Sabari, MD rank among oncology KOLs in 2026?

Joshua Sabari, MD ranks #47 among US lung cancer KOLs on X in 2026, based on engagement from fellow physicians (KOL Pulse rankings, updated November 10, 2026).

What did Joshua Sabari, MD present at oncology meetings in 2026?

DC Lung 2026 (debate): How do we approach borderline resectable EGFR mutant NSCLC: NeoADAURA or LAURA?.

Does Joshua Sabari, MD receive industry payments?

CMS Open Payments lists $154,263 in 2025 general payments. Source: CMS Open Payments, program year 2025.

See something wrong? Report an issue with this profile.

KOL Pulse analysis · Reviewed by Brian Shields, Founder, KOL Pulse · Updated